e-Therapeutics plc Further re: Directors' Shareholdings (5273L)
04 October 2016 - 12:03AM
UK Regulatory
TIDMETX
RNS Number : 5273L
e-Therapeutics plc
03 October 2016
e-Therapeutics plc
('e-Therapeutics' or 'the Company')
Further re: Directors' Shareholdings
3 October 2016, Oxford and Newcastle, UK: Further to
e-Therapeutics' announcement on 21 September 2016, the Company
announces the following additional detail on the increase to Sean
Nicolson's shareholding in the Company; this information is made in
accordance with the requirements of the EU Market Abuse
Regulation.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial
responsibilities/person closely associated
---- ------------------------------------------------------------
a) Name Sean Nicolson
---- ------------------------- ---------------------------------
2 Reason for the notification
---- ------------------------------------------------------------
a) Position/status Director
---- ------------------------- ---------------------------------
b) Initial Amendment
notification
/Amendment
---- ------------------------- ---------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
---- ------------------------------------------------------------
a) Name e-Therapeutics plc
---- ------------------------- ---------------------------------
b) Legal Entity N/A
Identifier
---- ------------------------- ---------------------------------
4 Details of the transaction(s): section
to be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
---- ------------------------------------------------------------
a) Description Ordinary shares of 0.1 pence
of the financial each
instrument,
type of instrument
Identification GB00B2823H99
code
---- -------------------------- --------------------------------
b) Nature of Award of shares
the transaction
---- -------------------------- --------------------------------
c) Currency GBP
---- -------------------------- --------------------------------
d) Price(s) and Price(s) Volume(s)
volume(s)
---- -------------------------- ------------------ ------------
14.55 pence 2,166
------------------------------------------------- ------------
e) Aggregated
information
- Aggregated
volume
- Price 2,166
- Aggregated 14.55 pence per share
total
GBP315.15
-------------------------- -------------------------------------
f) Date of the 21 September 2016
transaction
---- -------------------------- --------------------------------
g) Place of the London Stock Exchange (AIM)
transaction
---- -------------------------- --------------------------------
Contacts:
e-Therapeutics plc Tel: +44 (0) 1993
Iain Ross, Chairman 883 125
Steve Medlicott, Finance Director www.etherapeutics.co.uk
Numis Securities Limited Tel: +44 (0) 207 260
Michael Meade / Freddie Barnfield 1000
(Corporate Finance) www.numis.com
James Black (Corporate Broking)
Instinctif Partners Tel: +44 (0) 207 457
Melanie Toyne-Sewell / Jayne 2020
Crook / Emma Barlow Email: e-therapeutics@instinctif.com
About e-Therapeutics plc
e-Therapeutics (AIM: ETX) is a drug discovery company with a
proprietary discovery platform based on advances in network
pharmacology and chemical biology. The Company is applying its
platform to the discovery of new drug candidates. The therapeutic
focus of the Company's activity is in immuno-oncology, addressing
drug resistance in targeted cancer therapies and anti-infectives.
The platform is highly productive, yielding multiple potent and
selective molecules at a much higher rate and more quickly than is
reported for conventional drug discovery.
e-Therapeutics has a variety of preclinical stage assets,
including ETS2300, telomerase inhibition in anti-cancer; ETS3100,
small molecule anti-TNF<ALPHA>; ETS2400, Hedgehog pathway
inhibition and ETS5200, broad spectrum antivirals. The Company has
recently completed a phase IIb clinical trial for ETS6103, a drug
to treat major depressive disorder.
The Company is fully funded to advance its drug discovery
programmes. It is based in Oxford and Newcastle, UK. For more
information, visit www.etherapeutics.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLLFIVIFLVIIR
(END) Dow Jones Newswires
October 03, 2016 09:03 ET (13:03 GMT)
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Apr 2024 to May 2024
E-therapeutics (LSE:ETX)
Historical Stock Chart
From May 2023 to May 2024